40 results about "Chronic cardiac failure" patented technology

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

One purpose of the present invention is to treat or prevent chronic heart failure. Provided are: a pharmaceutical composition for treating or preventing chronic heart failure, said composition comprising a compound that inhibits SGLT1 or a pharmaceutically acceptable salt thereof; and a treatment or prevention method for chronic heart failure, said method being characterized by comprising administering a compound that inhibits SGLT1 or a pharmaceutically acceptable salt thereof.

The invention provides a cardiac targeting nano drug delivery carrier based on recombinant apolipoprotein, a system, a preparation method and application. The cardiac targeting nano drug delivery carrier comprises a nano carrier core and a functional layer covalently coupled to the surface of the nano carrier core, the nano carrier core comprises an amphiphilic copolymer formed by polylactic acid-glycolic acid and polyethylene glycol; the functional layer comprises recombinant apolipoprotein A-I and heart targeting peptide; the recombinant apolipoprotein A-I contains mutation sites E191A and F225W, and the recombinant apolipoprotein A-I contains mutation sites F225W; the amino acid sequence of the recombinant apolipoprotein A-I is as shown in SEQ ID NO: 1. The cardiac targeting nano drug delivery system based on the recombinant apolipoprotein has the functions of long circulation, cardiac targeting and coordinated regulation and control of metabolism and inflammation, and can be used for precise treatment of chronic heart failure.

FIELD: cardiology.SUBSTANCE: used as a component of the first stage of cardiac rehabilitation in patients with chronic heart failure (CHF), as well as an auxiliary component at all stages of cardiac rehabilitation. Warm-up exercises are performed – stretching exercises and movements in the joints of the upper body, followed by a basic set of breathing exercises lasting from 15 to 30 minutes, at least once a day, at least 5 days a week, for at least 8 weeks. At the first stage, the main set of exercises includes four exercises performed in sequence: abdominal breathing, chest breathing, breathing involving the shoulder muscles, breathing slowing. The first three exercises are performed for 5–10 breathing cycles with an interval between exercises of at least 1 minute, the fourth exercise contains 5–15 cycles, where each cycle includes an inhalation through the first nostril, followed by an exhalation and inhalation through the second nostril, then an exhalation through the first nostril . In the second and subsequent stages, the main set of exercises includes two exercises performed sequentially: an exercise for full breathing and an exercise for slowing down breathing. The full breathing exercise involves sequentially performing abdominal breathing, chest breathing, and breathing with the involvement of the shoulder muscles throughout one inhalation. The exhalation is performed in reverse order. The number of cycles of the full breathing exercise at the second stage is 15–20. The duration of each stage is at least 2 weeks, where at each subsequent stage, starting from the second one, the duration of the exercises performed in the main complex is increased by increasing the number of exercise cycles. Also the duration of inhalation and exhalation is increased when performing exercises to slow down breathing. The method improves the biomechanics of breathing: increases the depth of breathing, reduces the frequency of respiratory movements, increases the efficiency of breathing and reduces the activity of the inspiratory metaboreflex.EFFECT: exercise tolerance in patients with CHF improves.3 cl, 6 dwg, 3 ex

One purpose of the present invention is to treat or prevent chronic heart failure. Provided are: a pharmaceutical composition for treating or preventing chronic heart failure, said composition comprising a compound that inhibits SGLT1 or a pharmaceutically acceptable salt thereof; and a treatment or prevention method for chronic heart failure, said method being characterized by comprising administering a compound that inhibits SGLT1 or a pharmaceutically acceptable salt thereof.

This application relates to a series of novel compounds that are selective inhibitors of phosphodiesterase type 9 ("PDE9") for the treatment of chronic heart failure. More specifically, this application relates to pyrazolo[3,4-d]pyrimidinone compounds for use in the treatment and prevention of chronic heart failure.

The invention discloses a method for constructing a chronic heart failure co-disease depression animal model through composite intervention, and belongs to the technical field of disease animal model construction. Firstly, a left anterior descending coronary branch ligation operation is performed on a mouse to construct a heart failure model, and then a depression model is constructed by constraining mouse superposition. After composite modeling, the systolic function of the mouse is obviously reduced, the activity ability is weakened, and myocardial fibrosis and hippocampal tissue damage occur, which indicates that the heart failure co-disease depression model is successfully modeled. The animal model construction method has a good application prospect in research on the pathogenesis, biomarkers and treatment means of heart failure co-disease depression.

This invention discloses a traditional Chinese medicine composition for the prevention and / or treatment of type 2 cardiorenal syndrome and its application. By weight, the raw materials of the traditional Chinese medicine composition include: Astragalus membranaceus 15-30 parts, Paeonia lactiflora 10-20 parts, Saposhnikovia divaricata 5-10 parts, Leonurus japonicus 9-30 parts, Massa fermentata 9-30 parts, Poria cocos 10-30 parts, Cinnamomum cassia twig 9-30 parts, Atractylodes macrocephala 10-30 parts, and Glycyrrhiza uralensis 2-10 parts. This traditional Chinese medicine composition is mainly targeted at patients with early-stage renal damage in type 2 cardiorenal syndrome due to spleen-yang deficiency and blood stasis obstructing the collaterals. It utilizes a combination of various traditional Chinese medicines, whose active ingredients synergistically enhance each other, thereby achieving the therapeutic effect of improving early-stage renal damage after chronic heart failure and delaying the pathological progression of type 2 cardiorenal syndrome.

The invention relates to the technical field of medicine, in particular to application of parishin E in preparation of medicine for preventing and / or treating mitochondrial dysfunction heart failure, and the heart failure particularly refers to chronic heart failure induced by anthracycline antitumor drugs and related to mitochondrial dysfunction. In-vitro experiments prove that the parishin E can remarkably improve the mitochondrial function of myocardial cells damaged by adriamycin and improve basic respiration, ATP (adenosine triphosphate) synthesis and maximum respiration capacity of the myocardial cells. In an animal model, the parishin E effectively improves heart function indexes and relieves pathological injuries such as myocardial fiber arrangement disorder and cavity enlargement. The invention provides a natural small molecule which is novel in mechanism and has development potential for clinically preventing and treating anthracycline cardiotoxicity.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The invention belongs to the field of biological medicine, and particularly relates to a traditional Chinese medicine composition for treating heart yin deficiency and myocardial fibrosis and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: 5-13 parts of lily, 5-13 parts of radix ophiopogonis, 3-9 parts of ginseng, 5-13 parts of radix scrophulariae, 3-9 parts of semen boitae and 1-5 parts of schisandra chinensis. The invention also provides a preparation method of the composition. The composition has the effects of reinforcing qi, nourishing yin, calming the heart and tranquilizing the mind, and can be used for preparing medicines for treating heart-yin deficiency and myocardial fibrosis or improving heart-yin deficiency symptoms. Experimental results show that the traditional Chinese medicine composition can significantly improve the heart function of a chronic heart failure model mouse, inhibit myocardial cell hypertrophy and collagen deposition, and down-regulate fibrosis-related gene expression. Clinical observation shows that the traditional Chinese medicine can effectively relieve the symptoms of palpitation, insomnia, dysphoria with smothery sensation and the like of patients with heart yin deficiency. The traditional Chinese medicine composition is clear in formula and controllable in quality, and a novel safe and effective traditional Chinese medicine choice is provided for treating heart yin deficiency related myocardial fibrosis.

The invention discloses a chronic heart failure phlegm syndrome biomarker and application thereof. The biomarker is selected from at least one of ENO1, H2BC12, PCOLCE and TUBA1B. The chronic heart failure phlegm syndrome biomarker provided by the invention has high sensitivity and specificity when being applied to clinical diagnosis or auxiliary diagnosis of chronic heart failure phlegm syndrome patients, and can effectively distinguish the chronic heart failure phlegm syndrome patients from healthy people and chronic heart failure non-phlegm syndrome patients; precise distinguishing and diagnosis of chronic heart failure phlegm syndrome patients are achieved, and the requirements for clinical fine diagnosis and treatment and personalized treatment scheme making are met.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The traditional Chinese medicine composition is prepared from the following components in parts by weight: 6 to 12 parts of herba epimedii, 10 to 30 parts of radix astragali seu hedysari, 6 to 12 parts of herba cistanche, 4 to 8 parts of radix bupleuri, 6 to 12 parts of ramulus cinnamomi, 10 to 30 parts of caulis spatholobi, 10 to 15 parts of radix paeoniae alba, 6 to 12 parts of semen trigonellae and 10 to 40 parts of corn stigma. According to the traditional Chinese medicine composition disclosed by the invention, all the medicines are combined to achieve the effects of warming yang, tonifying qi, promoting blood circulation, inducing diuresis, warming and tonifying kidney yang in lower jiao and stirring qi in triple jiao.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a healthy energy supporting, yang warming and meridian dredging paste which is technically characterized by being prepared from honey-fried ephedra, wine-processed cornus, safflower, red paeony root, stevia rebaudiana, prepared common monkshood daughter root, Chinese yam, kudzuvine root, prepared rhizome of rehmannia, platycodon grandiflorum, pollen typhae, ligusticum wallichii, angelica sinensis, radix achyranthis bidentatae, astragalus membranaceus, asarum, radix bupleuri, liquorice, peach kernel, lignum dalbergiae odoriferae and fructus aurantii according to a specific weight part ratio. According to the ointment formula, the theory of Zheng method of Yandezhi teaching professor and the experience of Radix Astragali-Radix Puerariae formula of Guizhongguang national medicine master are fused, a treatment system which warms yang, benefits qi, promotes blood circulation, removes blood stasis, strengthens the body resistance and dredges collaterals is established, and the ointment formula accurately aims at the core pathogenesis of yang deficiency and blood stasis type coronary heart disease angina pectoris and chronic heart failure. Clinical tests prove that the ointment is remarkably superior to conventional treatment (Plt; 0.05) in the aspects of improving traditional Chinese medicine syndromes and improving heart functions, and is good in safety; moreover, the preparation is an oral ointment, is moist and sweet in quality, is convenient to take for a long time, and has remarkable clinical application value and popularization prospect.

The present application belongs to the field of biological medicine, and relates to a traditional Chinese medicine composition for treating chronic heart failure. The traditional Chinese medicine composition comprises the following traditional Chinese medicinal materials or is prepared based on raw medicinal materials comprising the following traditional Chinese medicines: Astragalus membranaceus (Fisch.) Bunge, Acanthopanax senticosus, black ginseng, Leonurus japonicus Houtt., Ophiopogon japonicus (Thunb.) Ker-Gawl., Eutrema latifolium, Schisandra chinensis (Turcz.) Baill., Cinnamomum cassia Presl and Polygonatum sibiricum. Clinical test results show that the traditional Chinese medicine composition significantly increases the systolic pressure and diastolic pressure of heart failure patients when treating chronic heart failure patients, not only has a significant effect, but also has a rapid effect. In addition, the traditional Chinese medicine composition significantly reduces the degree of cardiac inflammation and significantly improves the cardiac function in an experimental autoimmune myocarditis mouse model. In an adriamycin-induced heart failure model SD rat, the traditional Chinese medicine composition also significantly improves the cardiac function, showing good treatment potential.

The invention relates to an application of camel milk exosome in preparation of a medicine for treating heart diseases. According to the invention, the camel milk exosome is used for preparing the medicine for treating heart diseases, especially for relieving chronic heart failure, and a brand-new, safe and effective treatment scheme is provided for protecting the heart.

To provide methods for determining whether a subject has or is at risk of having heart failure, particularly heart failure with a reduced left ventricular ejection fraction (HFREF) and a heart failure with a preserved left ventricular ejection fraction (HFPEF).SOLUTION: The methods comprise determining the level of selected miRNA(s) observed in a sample obtained from the subject, where an altered level of the miRNA(s) compared to a control indicates that the subject has heart failure or is at risk of developing heart failure. Also included are methods of determining an altered risk of death or disease progression to hospitalization and to death based on alteration of selected miRNAs in a sample from the subject, and kits thereof.SELECTED DRAWING: Figure 1

The invention relates to a method for determining whether a subject diagnosed with a cardiovascular disease should be prescribed a remote patient management, the method comprising measuring particular biomarkers in a sample from said patient. The invention therefore relates to a method for therapy guidance, stratification and / or monitoring of a remote patient management for a patient diagnosed with a cardiovascular disease, comprising providing at least one sample of a patient, determining a level of at least one biomarker selected from the group consisting of proADM, proBNP and proANP or fragment(s) and comparing said level of the at least one biomarker to one or more reference values, wherein said level is indicative of prescribing or not prescribing a remote patient management for said patient. In some embodiments a low benefit level of the at least one biomarker is indicative of not prescribing a remote patient management, whereas in some embodiments a high benefit level of the at least one biomarker is indicative of prescribing a remote patient management. In some embodiments the cardiovascular disease is heart failure, in particular a chronic heart failure that has led to a hospitalization within the last 12 months.

The present disclosure relates to compositions and methods, including prodrugs of (S)-3-(3-(((3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzo[d]azepin-2-one that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, sinus tach (e.g. inappropriate sinus tachycardia (IST)), postural orthostatic tachycardia syndrome (POTS), coronavirus (COVID-19) (e.g. long COVID) and COVID-associated cardiovascular abnormalities, supraventricular tachycardia (SVT), tachycardia (e.g. rapid heart rate, atrial tachycardia), heart failure (e.g. congestive heart failure (CHF), systolic heart failure, pediatric heart failure, chronic heart failure), myocardial ischaemia, angina (e.g. angina pectoris), myocardial infarct, rhythm disturbances (e.g. supraventricular rhythm disturbances), chest pain, cardiomyopathy, coronary artery disease, and left ventricular dysfunction (LVD).

The traditional Chinese medicine physiotherapy instrument comprises a chair body, the chair body comprises a cushion body, armrest bodies are fixedly arranged at the two ends of the cushion body, and meanwhile, one end of the cushion body is rotationally connected with a backrest body through an angle adjusting module, so that the angle of the backrest can be flexibly adjusted; a traditional Chinese medicine physical therapy module B is fixedly arranged on the inner side surface of the armrest body, and the traditional Chinese medicine physical therapy module B promotes volatilization of traditional Chinese medicine components in an internal traditional Chinese medicine storage bag in a heating mode, so that the traditional Chinese medicine physical therapy effect is achieved; compared with an oral traditional Chinese medicine which needs to be taken for a long time and possibly stimulates the gastrointestinal tract, the physical therapy mode of the instrument avoids the problems, and the compliance of a patient is improved.

The invention provides a detection method of a traditional Chinese medicine composition for treating chronic heart failure. The detection method comprises thin-layer identification of eight medicinal material components, namely salvia miltiorrhiza, radix paeoniae rubra, fructus amomi, cassia twig, semen plantaginis, ginseng, rhizoma alismatis and herba leonuri. The identification method has the advantages of high detection speed and relatively comprehensive relative components of qualitative detection indexes. The invention further establishes a method for detecting the content of six traditional Chinese medicine effective substance components including ginsenosides Rg1, Re and Rb1, salvianolic acid B, paeoniflorin and cinnamaldehyde, and the method has the advantages of accuracy, reliability, simplicity, convenience, feasibility and good stability. The method can be applied to the quality detection standard of the ginseng-monkshood heart-benefiting traditional Chinese medicine composition, so that the internal quality of the composition is guaranteed.

The present invention belongs to the technical field of traditional Chinese medicine network pharmacology analysis, and particularly relates to a method for analyzing the mechanism of action of Daxie Feitang in preventing and treating chronic heart failure based on network pharmacology and experimental verification. The present invention has developed a new application of Daxie Feitang, that is, using it as a drug for treating chronic heart failure, and for the first time, a method for analyzing its mechanism of treating chronic heart failure by combining network pharmacology and experimental verification is proposed; on the one hand, through network pharmacology, the key action targets and related pathways of Daxie Feitang in treating chronic heart failure are obtained, and then through GO and KEGG enrichment analysis, it is speculated that the mechanism of action of Daxie Feitang in treating chronic heart failure is related to TNF and IL6; on the other hand, through animal experiments, it is further verified that Daxie Feitang has a significant improvement effect on the serum cardiac function NT-proBNP, inflammatory factors, urinary AQP2, and serum AVP content in rats, providing scientific theoretical and data support for the application of Daxie Feitang in chronic heart failure.

The invention discloses an exercise rehabilitation analysis management system based on chronic heart failure patients, relates to the technical field of intelligent rehabilitation medical treatment, and solves the problem that many rehabilitation schemes in the prior art lack full consideration of individual differences of patients. And accurate layering and personalized design cannot be carried out according to factors such as age, gender, severity of illness state and other basic diseases of the patient. The system comprises a data acquisition unit, a standard data correction unit, an analysis and comparison unit and an exercise rehabilitation scheme pushing unit, an exercise scheme can be formulated and adjusted according to specific conditions of a patient, and abnormal conditions can be found and processed in time through real-time data monitoring. In addition, by comprehensively considering individual differences of the patients, dynamically correcting key indexes, monitoring motion data in real time, giving an alarm in time and optimizing and popularizing the scheme based on data driving, individuation, precision and safety of the rehabilitation scheme of the chronic heart failure patients are remarkably improved.

The present application relates to acetaldehyde dehydrogenase 1 family member A3, and particularly to the application of acetaldehyde dehydrogenase 1 family member A3 and its inhibitor in the preparation of a drug for chronic heart failure. The present application discloses the application of acetaldehyde dehydrogenase 1 family member A3 as a drug target in the preparation of a drug for chronic heart failure. The present application first discloses the correlation between acetaldehyde dehydrogenase 1 family member A3 and chronic heart failure, and confirms that the vascular endothelial injury can be improved by specific knockdown or interference of ALDH1A3 to treat chronic heart failure, which indicates that ALDH1A3 can become a new target for treating chronic heart failure or cardiovascular diseases. Therefore, acetaldehyde dehydrogenase 1 family member A3 can be used as a target for screening a drug for preventing, relieving and / or treating chronic heart failure.

The invention discloses a chronic heart failure blood stasis syndrome biomarker and application thereof. The biomarker is selected from at least one of AFM, PCSK9 and APOC1. The chronic heart failure blood stasis syndrome biomarker provided by the invention has high sensitivity and specificity when being applied to clinical diagnosis or auxiliary diagnosis of chronic heart failure blood stasis syndrome patients, and can effectively distinguish the chronic heart failure blood stasis syndrome patients from healthy people and chronic heart failure non-blood stasis syndrome patients; reliable basis and practical guidance can be provided for clinical diagnosis and drug treatment of the blood stasis syndrome of the chronic heart failure, the accuracy of clinical diagnosis of the heart failure is improved, and the accuracy and standardization degree of traditional Chinese medicine syndrome differentiation diagnosis are improved.

The invention provides a chronic heart failure traditional Chinese medicine syndrome type identification method and device, and relates to the technical field of biological data analysis, and the method comprises the steps: obtaining a to-be-detected heart rate variability data set, dividing the to-be-detected heart rate variability data set into a to-be-detected time domain data set and a to-be-detected frequency domain data set, inputting the to-be-tested time domain data set into a first final traditional Chinese medicine syndrome type identification model for traditional Chinese medicine syndrome type prediction to obtain a first traditional Chinese medicine syndrome type probability set; inputting the to-be-measured frequency domain data set into a second final traditional Chinese medicine syndrome type identification model for traditional Chinese medicine syndrome type prediction to obtain a second traditional Chinese medicine syndrome type probability set; and performing weighted addition and maximum probability selection on the first traditional Chinese medicine syndrome type probability set and the second traditional Chinese medicine syndrome type probability set to obtain a final traditional Chinese medicine syndrome type probability, and obtaining a final chronic heart failure traditional Chinese medicine syndrome type text according to the final traditional Chinese medicine syndrome type probability.

The present invention provides a method of conducting a sleep analysis by collecting physiologic and kinetic data from a subject, preferably via a wireless in-home data acquisition system, while the subject attempts to sleep at home. The sleep analysis, including clinical and research sleep studies and cardiorespiratory studies, can be used in the diagnosis of sleeping disorders and other diseases or conditions with sleep signatures, such as Parkinson's, epilepsy, chronic heart failure, chronic obstructive pulmonary disorder, or other neurological, cardiac, pulmonary, or muscular disorders. The method of the present invention can also be used to determine if environmental factors at the subject's home are preventing restorative sleep.